Poldine methylsulfate is a synthetic quaternary ammonium compound that acts as an anticholinergic agent. Its synthesis involves the reaction of poldine with methylsulfate. Poldine methylsulfate exhibits a wide range of pharmacological effects, including inhibition of acetylcholine activity at muscarinic receptors, leading to bronchodilation, reduced gastric secretions, and decreased motility of the gastrointestinal tract. It is primarily used in the treatment of gastrointestinal disorders like peptic ulcer disease and irritable bowel syndrome, as well as for controlling symptoms associated with Parkinson's disease. The research on poldine methylsulfate primarily focuses on its therapeutic potential in various conditions, including its efficacy, safety profile, and interactions with other drugs. The compound is also studied for its potential use in ophthalmology to treat conditions like mydriasis and cycloplegia. Its effects on the autonomic nervous system and its ability to modulate cholinergic signaling pathways make it a subject of ongoing research.'
ID Source | ID |
---|---|
PubMed CID | 11017 |
CHEMBL ID | 2106739 |
SCHEMBL ID | 250977 |
MeSH ID | M0096976 |
Synonym |
---|
metilsulfate de poldine |
poldine methylsulphate |
poldine metilsulfate [inn] |
i.s. 499 |
nacton |
pyrrolidinium 2-(((hydroxydiphenylacetyl)oxy)methyl)-1,1-dimethyl-, methyl sulfate |
564c0w9848 , |
metilsulfato de poldina |
2-(hydroxymethyl)-1,1-dimethylpyrrolidinium methyl sulfate benzilate |
poldini metilsulfas |
metilsulfato de poldina [inn-spanish] |
poldine methylsulfate [usan:usp] |
unii-564c0w9848 |
poldoni methylsulfas |
metilsulfate de poldine [inn-french] |
mcn-r-726-47 |
poldini metilsulfas [inn-latin] |
einecs 208-894-6 |
D05535 |
545-80-2 |
poldine metilsulfate |
poldine methylsulfate (usan) |
poldine methylsulfate |
is-499 |
CHEMBL2106739 |
poldine methyl methosulfate |
i.s.-499 |
nactate |
clb-499 |
alfaland |
poldine metilsulphate |
poldine methosulfate |
pyrrolidinium, 2-(((hydroxydiphenylacetyl)oxy)methyl)-1,1-dimethyl-, methyl sulfate (salt) |
pyrrolidinium, 2-(((2-hydroxy-2,2-diphenylacetyl)oxy)methyl)-1,1-dimethyl-, methyl sulfate (1:1) |
poldine metilsulfate [mart.] |
pyrrolidinium, 2-(hydroxymethyl)-1,1-dimethyl-, methyl sulfate, benzilate |
2-(hydroxymethyl)-1,1-dimethylpyrrolidinium methyl sulphate benzilate |
(1-methyl-2-pyrrolidinyl)methyl benzilate methyl methosulfate |
poldine metilsulfate [who-dd] |
poldine methylsulfate [usan] |
poldine methylsulfate [mi] |
SCHEMBL250977 |
poldinmetilsulfat |
2-({[hydroxy(diphenyl)acetyl]oxy}methyl)-1,1-dimethylpyrrolidin-1-ium methyl sulfate |
DTXSID80969686 |
Q27261372 |
(1,1-dimethylpyrrolidin-1-ium-2-yl)methyl 2-hydroxy-2,2-diphenylacetate;methyl sulfate |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 9 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.78) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |